dbSNP Short Genetic Variations
Welcome to the Reference SNP (rs) Report
All alleles are reported in the Forward orientation. Click on the Variant Details tab for details on Genomic Placement, Gene, and Amino Acid changes. HGVS names are in the HGVS tab.
Reference SNP (rs) Report
This page reports data for a single dbSNP Reference SNP variation (RefSNP or rs) from the new redesigned dbSNP build.
Top of the page reports a concise summary for the rs, with more specific details included in the corresponding tabs below.
All alleles are reported in the Forward orientation. Use the Genomic View to inspect the nucleotides flanking the variant, and its neighbors.
For more information see Help documentation.
rs9923231
Current Build 157
Released September 3, 2024
- Organism
- Homo sapiens
- Position
-
chr16:31096368 (GRCh38.p14) Help
The anchor position for this RefSNP. Includes all nucleotides potentially affected by this change, thus it can differ from HGVS, which is right-shifted. See here for details.
- Alleles
- C>A / C>G / C>T
- Variation Type
- SNV Single Nucleotide Variation
- Frequency
-
T=0.322691 (85413/264690, TOPMED)T=0.380890 (78912/207178, ALFA)T=0.317274 (47296/149070, GnomAD_genomes) (+ 16 more)
- Clinical Significance
- Reported in ClinVar
- Gene : Consequence
-
VKORC1 : 2KB Upstream VariantLOC124903680 : 2KB Upstream Variant
- Publications
- 263 citations
- Genomic View
- See rs on genome
ALFA Allele Frequency
The ALFA project provide aggregate allele frequency from dbGaP. More information is available on the project page including descriptions, data access, and terms of use.
Release Version: 20231103111315
| Population | Group | Sample Size | Ref Allele | Alt Allele | Ref HMOZ | Alt HMOZ | HTRZ | HWEP |
|---|---|---|---|---|---|---|---|---|
| Total | Global | 207178 | C=0.619110 | T=0.380890 | 0.389935 | 0.151715 | 0.45835 | 32 |
| European | Sub | 179666 | C=0.607639 | T=0.392361 | 0.371111 | 0.155834 | 0.473056 | 4 |
| African | Sub | 7094 | C=0.8924 | T=0.1076 | 0.795884 | 0.010995 | 0.193121 | 0 |
| African Others | Sub | 264 | C=0.958 | T=0.042 | 0.916667 | 0.0 | 0.083333 | 0 |
| African American | Sub | 6830 | C=0.8899 | T=0.1101 | 0.791215 | 0.01142 | 0.197365 | 0 |
| Asian | Sub | 702 | C=0.121 | T=0.879 | 0.017094 | 0.774929 | 0.207977 | 0 |
| East Asian | Sub | 556 | C=0.095 | T=0.905 | 0.010791 | 0.820144 | 0.169065 | 0 |
| Other Asian | Sub | 146 | C=0.219 | T=0.781 | 0.041096 | 0.60274 | 0.356164 | 0 |
| Latin American 1 | Sub | 842 | C=0.719 | T=0.281 | 0.527316 | 0.090261 | 0.382423 | 1 |
| Latin American 2 | Sub | 6888 | C=0.5530 | T=0.4470 | 0.307782 | 0.2018 | 0.490418 | 0 |
| South Asian | Sub | 5042 | C=0.7959 | T=0.2041 | 0.635065 | 0.043237 | 0.321698 | 0 |
| Other | Sub | 6944 | C=0.6122 | T=0.3878 | 0.386809 | 0.162442 | 0.450749 | 5 |
Frequency tab displays a table of the reference and alternate allele frequencies reported by various studies and populations. Table lines, where Population="Global" refer to the entire study population, whereas lines, where Group="Sub", refer to a study-specific population subgroupings (i.e. AFR, CAU, etc.), if available. Frequency for the alternate allele (Alt Allele) is a ratio of samples observed-to-total, where the numerator (observed samples) is the number of chromosomes in the study with the minor allele present (found in "Sample size", where Group="Sub"), and the denominator (total samples) is the total number of all chromosomes in the study for the variant (found in "Sample size", where Group="Study-wide" and Population="Global").
Download| Study | Population | Group | Sample Size | Ref Allele | Alt Allele |
|---|---|---|---|---|---|
| TopMed | Global | Study-wide | 264690 | C=0.677309 | T=0.322691 |
| Allele Frequency Aggregator | Total | Global | 207178 | C=0.619110 | T=0.380890 |
| Allele Frequency Aggregator | European | Sub | 179666 | C=0.607639 | T=0.392361 |
| Allele Frequency Aggregator | African | Sub | 7094 | C=0.8924 | T=0.1076 |
| Allele Frequency Aggregator | Other | Sub | 6944 | C=0.6122 | T=0.3878 |
| Allele Frequency Aggregator | Latin American 2 | Sub | 6888 | C=0.5530 | T=0.4470 |
| Allele Frequency Aggregator | South Asian | Sub | 5042 | C=0.7959 | T=0.2041 |
| Allele Frequency Aggregator | Latin American 1 | Sub | 842 | C=0.719 | T=0.281 |
| Allele Frequency Aggregator | Asian | Sub | 702 | C=0.121 | T=0.879 |
| gnomAD v4 - Genomes | Global | Study-wide | 149070 | C=0.682726 | T=0.317274 |
| gnomAD v4 - Genomes | European | Sub | 78544 | C=0.62034 | T=0.37966 |
| gnomAD v4 - Genomes | African | Sub | 41504 | C=0.90023 | T=0.09977 |
| gnomAD v4 - Genomes | American | Sub | 15262 | C=0.60857 | T=0.39143 |
| gnomAD v4 - Genomes | East Asian | Sub | 5172 | C=0.1083 | T=0.8917 |
| gnomAD v4 - Genomes | South Asian | Sub | 4824 | C=0.8219 | T=0.1781 |
| gnomAD v4 - Genomes | Ashkenazi Jewish | Sub | 3472 | C=0.5006 | T=0.4994 |
| gnomAD v4 - Genomes | Middle Eastern | sub | 292 | C=0.466 | T=0.534 |
| Korean Genome Project 4K | KOREAN | Study-wide | 7234 | C=0.0748 | T=0.9252 |
| 1000Genomes_30X | Global | Study-wide | 6404 | C=0.6565 | T=0.3435 |
| 1000Genomes_30X | African | Sub | 1786 | C=0.9423 | T=0.0577 |
| 1000Genomes_30X | Europe | Sub | 1266 | C=0.6137 | T=0.3863 |
| 1000Genomes_30X | South Asian | Sub | 1202 | C=0.8569 | T=0.1431 |
| 1000Genomes_30X | East Asian | Sub | 1170 | C=0.1145 | T=0.8855 |
| 1000Genomes_30X | American | Sub | 980 | C=0.592 | T=0.408 |
| 1000Genomes | Global | Study-wide | 5008 | C=0.6444 | T=0.3556 |
| 1000Genomes | African | Sub | 1322 | C=0.9455 | T=0.0545 |
| 1000Genomes | East Asian | Sub | 1008 | C=0.1151 | T=0.8849 |
| 1000Genomes | Europe | Sub | 1006 | C=0.6123 | T=0.3877 |
| 1000Genomes | South Asian | Sub | 978 | C=0.855 | T=0.145 |
| 1000Genomes | American | Sub | 694 | C=0.589 | T=0.411 |
| Genetic variation in the Estonian population | Estonian | Study-wide | 4480 | C=0.6538 | T=0.3462 |
| The Avon Longitudinal Study of Parents and Children | PARENT AND CHILD COHORT | Study-wide | 3854 | C=0.6321 | T=0.3679 |
| UK 10K study - Twins | TWIN COHORT | Study-wide | 3708 | C=0.6297 | T=0.3703 |
| KOREAN population from KRGDB | KOREAN | Study-wide | 2930 | C=0.0782 | A=0.0000, G=0.0000, T=0.9218 |
| HapMap | Global | Study-wide | 1892 | C=0.6210 | T=0.3790 |
| HapMap | American | Sub | 770 | C=0.561 | T=0.439 |
| HapMap | African | Sub | 692 | C=0.910 | T=0.090 |
| HapMap | Asian | Sub | 254 | C=0.083 | T=0.917 |
| HapMap | Europe | Sub | 176 | C=0.523 | T=0.477 |
| Genome of the Netherlands Release 5 | Genome of the Netherlands | Study-wide | 998 | C=0.627 | T=0.373 |
| CNV burdens in cranial meningiomas | Global | Study-wide | 792 | C=0.091 | T=0.909 |
| CNV burdens in cranial meningiomas | CRM | Sub | 792 | C=0.091 | T=0.909 |
| Northern Sweden | ACPOP | Study-wide | 600 | C=0.627 | T=0.373 |
| SGDP_PRJ | Global | Study-wide | 346 | C=0.260 | T=0.740 |
| Qatari | Global | Study-wide | 216 | C=0.542 | T=0.458 |
| A Vietnamese Genetic Variation Database | Global | Study-wide | 214 | C=0.182 | T=0.818 |
| Siberian | Global | Study-wide | 44 | C=0.27 | T=0.73 |
| The Danish reference pan genome | Danish | Study-wide | 40 | C=0.53 | T=0.47 |
Help
Variant Details tab shows known variant placements on genomic sequences: chromosomes (NC_), RefSeqGene, pseudogenes or genomic regions (NG_), and in a separate table: on transcripts (NM_) and protein sequences (NP_). The corresponding transcript and protein locations are listed in adjacent lines, along with molecular consequences from Sequence Ontology. When no protein placement is available, only the transcript is listed. Column "Codon[Amino acid]" shows the actual base change in the format of "Reference > Alternate" allele, including the nucleotide codon change in transcripts, and the amino acid change in proteins, respectively, allowing for known ribosomal slippage sites. To view nucleotides adjacent to the variant use the Genomic View at the bottom of the page - zoom into the sequence until the nucleotides around the variant become visible.
Genomic Placements
| Sequence name | Change |
|---|---|
| GRCh38.p14 chr 16 | NC_000016.10:g.31096368C>A |
| GRCh38.p14 chr 16 | NC_000016.10:g.31096368C>G |
| GRCh38.p14 chr 16 | NC_000016.10:g.31096368C>T |
| GRCh37.p13 chr 16 | NC_000016.9:g.31107689C>A |
| GRCh37.p13 chr 16 | NC_000016.9:g.31107689C>G |
| GRCh37.p13 chr 16 | NC_000016.9:g.31107689C>T |
| VKORC1 RefSeqGene (LRG_582) | NG_011564.1:g.3588G>T |
| VKORC1 RefSeqGene (LRG_582) | NG_011564.1:g.3588G>C |
| VKORC1 RefSeqGene (LRG_582) | NG_011564.1:g.3588G>A |
Gene: VKORC1, vitamin K epoxide reductase complex subunit 1
(minus strand)
:
2KB Upstream Variant
| Molecule type | Change | Amino acid[Codon] | SO Term |
|---|---|---|---|
| VKORC1 transcript variant 3 | NM_001311311.2:c. | N/A | Upstream Transcript Variant |
| VKORC1 transcript variant 1 | NM_024006.6:c. | N/A | Upstream Transcript Variant |
| VKORC1 transcript variant 2 | NM_206824.3:c. | N/A | Upstream Transcript Variant |
Gene: LOC124903680, uncharacterized LOC124903680
(minus strand)
:
2KB Upstream Variant
| Molecule type | Change | Amino acid[Codon] | SO Term |
|---|---|---|---|
| LOC124903680 transcript | XM_047435012.1:c. | N/A | Upstream Transcript Variant |
Help
Clinical Significance tab shows a list of clinical significance entries from ClinVar associated with the variation, per allele. Click on the RCV accession (i.e. RCV000001615.2) or Allele ID (i.e. 12274) to access full ClinVar report.
Allele: C= (allele ID:
176160
)
| ClinVar Accession | Disease Names | Clinical Significance |
|---|---|---|
| RCV000152659.13 | Warfarin response | Drug-Response |
Allele: T (allele ID:
17250
)
| ClinVar Accession | Disease Names | Clinical Significance |
|---|---|---|
| RCV000002295.15 | Warfarin response | Pathogenic,Drug-Response |
| RCV000377657.13 | not provided | Other |
| RCV000603173.9 | not specified | Likely-Benign |
| RCV001787364.9 | phenprocoumon response - Dosage | Drug-Response |
| RCV001787365.11 | phenprocoumon response - Toxicity | Drug-Response |
| RCV001787366.10 | warfarin response - Toxicity | Drug-Response |
| RCV003150805.9 | Venous thromboembolism | Protective |
| RCV003227593.8 | warfarin response - Dosage | Drug-Response |
| RCV003227594.8 | acenocoumarol response - Dosage | Drug-Response |
| RCV003227595.10 | warfarin response - Efficacy | Drug-Response |
| RCV003952337.1 | VKORC1-related disorder | Likely-Benign |
| RCV003993732.1 | See cases | Uncertain-Significance |
| RCV003996074.1 | Thrombus | Uncertain-Significance |
Help
Aliases tab displays HGVS names representing the variant placements and allele changes on genomic, transcript and protein sequences, per allele. HGVS name is an expression for reporting sequence accession and version, sequence type, position, and allele change. The column "Note" can have two values: "diff" means that there is a difference between the reference allele (variation interval) at the placement reported in HGVS name and the reference alleles reported in other HGVS names, and "rev" means that the sequence of this variation interval at the placement reported in HGVS name is in reverse orientation to the sequence(s) of this variation in other HGVS names not labeled as "rev".
| Placement | C= | A | G | T |
|---|---|---|---|---|
| GRCh38.p14 chr 16 | NC_000016.10:g.31096368= | NC_000016.10:g.31096368C>A | NC_000016.10:g.31096368C>G | NC_000016.10:g.31096368C>T |
| GRCh37.p13 chr 16 | NC_000016.9:g.31107689= | NC_000016.9:g.31107689C>A | NC_000016.9:g.31107689C>G | NC_000016.9:g.31107689C>T |
| VKORC1 RefSeqGene (LRG_582) | NG_011564.1:g.3588= | NG_011564.1:g.3588G>T | NG_011564.1:g.3588G>C | NG_011564.1:g.3588G>A |
Help
Submissions tab displays variations originally submitted to dbSNP, now supporting this RefSNP cluster (rs). We display Submitter handle, Submission identifier, Date and Build number, when the submission appeared for the first time. Direct submissions to dbSNP have Submission ID in the form of an ss-prefixed number (ss#). Other supporting variations are listed in the table without ss#.
133 SubSNP,
21 Frequency,
14 ClinVar
submissions
| No | Submitter | Submission ID | Date (Build) |
|---|---|---|---|
| 1 | BCM_SSAHASNP | ss13761958 | Dec 05, 2003 (119) |
| 2 | SSAHASNP | ss21316156 | Apr 05, 2004 (121) |
| 3 | PGA-UW-FHCRC | ss28527760 | Dec 02, 2004 (126) |
| 4 | ILLUMINA | ss75181539 | Dec 07, 2007 (129) |
| 5 | HGSV | ss77595664 | Dec 07, 2007 (129) |
| 6 | HGSV | ss83709285 | Dec 15, 2007 (130) |
| 7 | BCMHGSC_JDW | ss90365531 | Mar 24, 2008 (129) |
| 8 | BGI | ss103290726 | Feb 21, 2009 (130) |
| 9 | PHARMGKB_PEAR | ss105108094 | Feb 06, 2009 (130) |
| 10 | PHARMGKB_PEAR | ss105109748 | Feb 06, 2009 (130) |
| 11 | 1000GENOMES | ss109298630 | Jan 23, 2009 (130) |
| 12 | KRIBB_YJKIM | ss119606770 | Dec 01, 2009 (131) |
| 13 | ENSEMBL | ss136659349 | Dec 01, 2009 (131) |
| 14 | ENSEMBL | ss136759876 | Dec 01, 2009 (131) |
| 15 | ILLUMINA | ss154517329 | Dec 01, 2009 (131) |
| 16 | GMI | ss157248916 | Dec 01, 2009 (131) |
| 17 | ILLUMINA | ss159691137 | Dec 01, 2009 (131) |
| 18 | ILLUMINA | ss161024963 | Dec 01, 2009 (131) |
| 19 | ILLUMINA | ss174928603 | Jul 04, 2010 (132) |
| 20 | BUSHMAN | ss201611298 | Jul 04, 2010 (132) |
| 21 | 1000GENOMES | ss227214761 | Jul 14, 2010 (132) |
| 22 | 1000GENOMES | ss237004905 | Jul 15, 2010 (132) |
| 23 | 1000GENOMES | ss243348946 | Jul 15, 2010 (132) |
| 24 | GMI | ss282493659 | May 04, 2012 (137) |
| 25 | GMI | ss287058906 | Apr 25, 2013 (138) |
| 26 | PJP | ss291944768 | May 09, 2011 (134) |
| 27 | ILLUMINA | ss410961014 | Sep 17, 2011 (135) |
| 28 | ILLUMINA | ss482018400 | May 04, 2012 (137) |
| 29 | ILLUMINA | ss482052529 | May 04, 2012 (137) |
| 30 | ILLUMINA | ss483002909 | Sep 08, 2015 (146) |
| 31 | ILLUMINA | ss485802687 | May 04, 2012 (137) |
| 32 | EXOME_CHIP | ss491507448 | May 04, 2012 (137) |
| 33 | ILLUMINA | ss537643660 | Sep 08, 2015 (146) |
| 34 | TISHKOFF | ss564870521 | Apr 25, 2013 (138) |
| 35 | SSMP | ss660625311 | Apr 25, 2013 (138) |
| 36 | ILLUMINA | ss779022956 | Sep 08, 2015 (146) |
| 37 | ILLUMINA | ss783347190 | Sep 08, 2015 (146) |
| 38 | ILLUMINA | ss784298467 | Sep 08, 2015 (146) |
| 39 | ILLUMINA | ss832609155 | Sep 08, 2015 (146) |
| 40 | ILLUMINA | ss833201796 | Jul 13, 2019 (153) |
| 41 | ILLUMINA | ss834485577 | Sep 08, 2015 (146) |
| 42 | EVA-GONL | ss992432591 | Aug 21, 2014 (142) |
| 43 | JMKIDD_LAB | ss1080589035 | Aug 21, 2014 (142) |
| 44 | 1000GENOMES | ss1355977395 | Aug 21, 2014 (142) |
| 45 | DDI | ss1427823814 | Apr 01, 2015 (144) |
| 46 | OMIM-CURATED-RECORDS | ss1505810760 | Dec 08, 2014 (142) |
| 47 | EVA_GENOME_DK | ss1577894834 | Apr 01, 2015 (144) |
| 48 | EVA_UK10K_ALSPAC | ss1634304827 | Apr 01, 2015 (144) |
| 49 | EVA_UK10K_TWINSUK | ss1677298860 | Apr 01, 2015 (144) |
| 50 | EVA_DECODE | ss1696467003 | Apr 01, 2015 (144) |
| 51 | EVA_SVP | ss1713536025 | Apr 01, 2015 (144) |
| 52 | ILLUMINA | ss1752190372 | Sep 08, 2015 (146) |
| 53 | WEILL_CORNELL_DGM | ss1935857494 | Feb 12, 2016 (147) |
| 54 | GENOMED | ss1968250986 | Jul 19, 2016 (147) |
| 55 | JJLAB | ss2028715725 | Sep 14, 2016 (149) |
| 56 | ILLUMINA | ss2094890071 | Dec 20, 2016 (150) |
| 57 | ILLUMINA | ss2095066090 | Dec 20, 2016 (150) |
| 58 | CLINVAR | ss2137495312 | Feb 23, 2017 (149) |
| 59 | USC_VALOUEV | ss2157129975 | Dec 20, 2016 (150) |
| 60 | HUMAN_LONGEVITY | ss2211738303 | Dec 20, 2016 (150) |
| 61 | SYSTEMSBIOZJU | ss2628850413 | Nov 08, 2017 (151) |
| 62 | ILLUMINA | ss2633311817 | Nov 08, 2017 (151) |
| 63 | ILLUMINA | ss2635063516 | Nov 08, 2017 (151) |
| 64 | GRF | ss2701637563 | Nov 08, 2017 (151) |
| 65 | GNOMAD | ss2942119714 | Nov 08, 2017 (151) |
| 66 | AFFY | ss2985066798 | Nov 08, 2017 (151) |
| 67 | AFFY | ss2985703212 | Nov 08, 2017 (151) |
| 68 | SWEGEN | ss3014335205 | Nov 08, 2017 (151) |
| 69 | BIOINF_KMB_FNS_UNIBA | ss3028180750 | Nov 08, 2017 (151) |
| 70 | CSHL | ss3351408497 | Nov 08, 2017 (151) |
| 71 | ILLUMINA | ss3627511089 | Oct 12, 2018 (152) |
| 72 | ILLUMINA | ss3631298626 | Oct 12, 2018 (152) |
| 73 | ILLUMINA | ss3633119161 | Oct 12, 2018 (152) |
| 74 | ILLUMINA | ss3633825137 | Oct 12, 2018 (152) |
| 75 | ILLUMINA | ss3634639923 | Oct 12, 2018 (152) |
| 76 | ILLUMINA | ss3635513480 | Oct 12, 2018 (152) |
| 77 | ILLUMINA | ss3636330245 | Oct 12, 2018 (152) |
| 78 | ILLUMINA | ss3637264907 | Oct 12, 2018 (152) |
| 79 | ILLUMINA | ss3638122215 | Oct 12, 2018 (152) |
| 80 | ILLUMINA | ss3640347242 | Oct 12, 2018 (152) |
| 81 | ILLUMINA | ss3643103536 | Oct 12, 2018 (152) |
| 82 | URBANLAB | ss3650498578 | Oct 12, 2018 (152) |
| 83 | ILLUMINA | ss3652107666 | Oct 12, 2018 (152) |
| 84 | ILLUMINA | ss3653838674 | Oct 12, 2018 (152) |
| 85 | EGCUT_WGS | ss3681408914 | Jul 13, 2019 (153) |
| 86 | EVA_DECODE | ss3699138570 | Jul 13, 2019 (153) |
| 87 | ACPOP | ss3741465828 | Jul 13, 2019 (153) |
| 88 | ILLUMINA | ss3744940351 | Jul 13, 2019 (153) |
| 89 | EVA | ss3753863708 | Jul 13, 2019 (153) |
| 90 | ILLUMINA | ss3772438653 | Jul 13, 2019 (153) |
| 91 | PACBIO | ss3788022296 | Jul 13, 2019 (153) |
| 92 | PACBIO | ss3793008645 | Jul 13, 2019 (153) |
| 93 | PACBIO | ss3797893537 | Jul 13, 2019 (153) |
| 94 | KHV_HUMAN_GENOMES | ss3819156746 | Jul 13, 2019 (153) |
| 95 | EVA | ss3834546941 | Apr 27, 2020 (154) |
| 96 | EVA | ss3840881041 | Apr 27, 2020 (154) |
| 97 | EVA | ss3846372066 | Apr 27, 2020 (154) |
| 98 | SGDP_PRJ | ss3884287739 | Apr 27, 2020 (154) |
| 99 | KRGDB | ss3933646439 | Apr 27, 2020 (154) |
| 100 | EVA | ss3984712159 | Apr 27, 2021 (155) |
| 101 | TOMMO_GENOMICS | ss6162174623 | Nov 03, 2024 (157) |
| 102 | TOMMO_GENOMICS | ss6162174624 | Nov 03, 2024 (157) |
| 103 | EVA | ss6271139551 | Nov 03, 2024 (157) |
| 104 | EVA | ss6316065000 | Nov 03, 2024 (157) |
| 105 | EVA | ss6322547373 | Nov 03, 2024 (157) |
| 106 | EVA | ss6327770855 | Nov 03, 2024 (157) |
| 107 | EVA | ss6333122280 | Nov 03, 2024 (157) |
| 108 | YEGNASUBRAMANIAN_LAB | ss6346564568 | Nov 03, 2024 (157) |
| 109 | EVA | ss6349909945 | Nov 03, 2024 (157) |
| 110 | KOGIC | ss6393708372 | Nov 03, 2024 (157) |
| 111 | GNOMAD | ss6995223683 | Nov 03, 2024 (157) |
| 112 | TOPMED | ss8012865347 | Nov 03, 2024 (157) |
| 113 | TOMMO_GENOMICS | ss8219197800 | Nov 03, 2024 (157) |
| 114 | 1000G_HIGH_COVERAGE | ss8300689691 | Nov 03, 2024 (157) |
| 115 | EVA | ss8315834795 | Nov 03, 2024 (157) |
| 116 | EVA | ss8423277073 | Nov 03, 2024 (157) |
| 117 | HUGCELL_USP | ss8494114949 | Nov 03, 2024 (157) |
| 118 | EVA | ss8511599265 | Nov 03, 2024 (157) |
| 119 | 1000G_HIGH_COVERAGE | ss8603179274 | Nov 03, 2024 (157) |
| 120 | SANFORD_IMAGENETICS | ss8624378657 | Nov 03, 2024 (157) |
| 121 | SANFORD_IMAGENETICS | ss8658769607 | Nov 03, 2024 (157) |
| 122 | TOMMO_GENOMICS | ss8773908237 | Nov 03, 2024 (157) |
| 123 | EVA | ss8799404562 | Nov 03, 2024 (157) |
| 124 | YY_MCH | ss8815894804 | Nov 03, 2024 (157) |
| 125 | EVA | ss8846314159 | Nov 03, 2024 (157) |
| 126 | EVA | ss8847461571 | Nov 03, 2024 (157) |
| 127 | EVA | ss8851549473 | Nov 03, 2024 (157) |
| 128 | EVA | ss8898849591 | Nov 03, 2024 (157) |
| 129 | EVA | ss8950183867 | Nov 03, 2024 (157) |
| 130 | EVA | ss8979483448 | Nov 03, 2024 (157) |
| 131 | EVA | ss8981800139 | Nov 03, 2024 (157) |
| 132 | EVA | ss8981800140 | Nov 03, 2024 (157) |
| 133 | EVA | ss8982263478 | Nov 03, 2024 (157) |
| 134 | 1000Genomes | NC_000016.9 - 31107689 | Oct 12, 2018 (152) |
| 135 | 1000Genomes_30X | NC_000016.10 - 31096368 | Nov 03, 2024 (157) |
| 136 | The Avon Longitudinal Study of Parents and Children | NC_000016.9 - 31107689 | Oct 12, 2018 (152) |
| 137 | Genetic variation in the Estonian population | NC_000016.9 - 31107689 | Oct 12, 2018 (152) |
| 138 | The Danish reference pan genome | NC_000016.9 - 31107689 | Apr 27, 2020 (154) |
| 139 | gnomAD v4 - Genomes | NC_000016.10 - 31096368 | Nov 03, 2024 (157) |
| 140 | Genome of the Netherlands Release 5 | NC_000016.9 - 31107689 | Apr 27, 2020 (154) |
| 141 | HapMap | NC_000016.10 - 31096368 | Apr 27, 2020 (154) |
| 142 | KOREAN population from KRGDB | NC_000016.9 - 31107689 | Apr 27, 2020 (154) |
| 143 | Korean Genome Project 4K | NC_000016.10 - 31096368 | Nov 03, 2024 (157) |
| 144 | Northern Sweden | NC_000016.9 - 31107689 | Jul 13, 2019 (153) |
| 145 | CNV burdens in cranial meningiomas | NC_000016.9 - 31107689 | Apr 27, 2021 (155) |
| 146 | Qatari | NC_000016.9 - 31107689 | Apr 27, 2020 (154) |
| 147 | SGDP_PRJ | NC_000016.9 - 31107689 | Apr 27, 2020 (154) |
| 148 | Siberian | NC_000016.9 - 31107689 | Apr 27, 2020 (154) |
| 149 |
38KJPN
Submission ignored due to conflicting rows: |
- | Nov 03, 2024 (157) |
| 150 |
38KJPN
Submission ignored due to conflicting rows: |
- | Nov 03, 2024 (157) |
| 151 | TopMed | NC_000016.10 - 31096368 | Apr 27, 2021 (155) |
| 152 | UK 10K study - Twins | NC_000016.9 - 31107689 | Oct 12, 2018 (152) |
| 153 | A Vietnamese Genetic Variation Database | NC_000016.9 - 31107689 | Jul 13, 2019 (153) |
| 154 | ALFA | NC_000016.10 - 31096368 | Nov 03, 2024 (157) |
| 155 | ClinVar | RCV000002295.15 | Nov 03, 2024 (157) |
| 156 | ClinVar | RCV000152659.13 | Nov 03, 2024 (157) |
| 157 | ClinVar | RCV000377657.13 | Nov 03, 2024 (157) |
| 158 | ClinVar | RCV000603173.9 | Nov 03, 2024 (157) |
| 159 | ClinVar | RCV001787364.9 | Nov 03, 2024 (157) |
| 160 | ClinVar | RCV001787365.11 | Nov 03, 2024 (157) |
| 161 | ClinVar | RCV001787366.10 | Nov 03, 2024 (157) |
| 162 | ClinVar | RCV003150805.9 | Nov 03, 2024 (157) |
| 163 | ClinVar | RCV003227593.8 | Nov 03, 2024 (157) |
| 164 | ClinVar | RCV003227594.8 | Nov 03, 2024 (157) |
| 165 | ClinVar | RCV003227595.10 | Nov 03, 2024 (157) |
| 166 | ClinVar | RCV003952337.1 | Nov 03, 2024 (157) |
| 167 | ClinVar | RCV003993732.1 | Nov 03, 2024 (157) |
| 168 | ClinVar | RCV003996074.1 | Nov 03, 2024 (157) |
Help
History tab displays RefSNPs (Associated ID) from previous builds (Build) that now support the current RefSNP, and the dates, when the history was updated for each Associated ID (History Updated).
| Associated ID | History Updated (Build) |
|---|---|
| rs17878363 | Mar 10, 2006 (126) |
| rs60511154 | May 26, 2008 (130) |
| rs117572127 | Aug 16, 2010 (132) |
Added to this RefSNP Cluster:
| Submission IDs | Observation SPDI | Canonical SPDI | Source RSIDs |
|---|---|---|---|
| 40823833, ss3933646439 | NC_000016.9:31107688:C:A | NC_000016.10:31096367:C:A | (self) |
| ss2137495312, ss6162174624 | NC_000016.10:31096367:C:A | NC_000016.10:31096367:C:A | (self) |
| ss105108094, ss105109748 | NT_010393.16:31047688:C:A | NC_000016.10:31096367:C:A | (self) |
| 40823833, ss3933646439 | NC_000016.9:31107688:C:G | NC_000016.10:31096367:C:G | (self) |
| ss105108094, ss105109748 | NT_010393.16:31047688:C:G | NC_000016.10:31096367:C:G | (self) |
| ss77595664, ss83709285, ss90365531, ss109298630, ss201611298, ss282493659, ss287058906, ss291944768, ss482018400, ss1696467003, ss1713536025, ss2094890071, ss2635063516, ss3643103536 | NC_000016.8:31015189:C:T | NC_000016.10:31096367:C:T | (self) |
| 69132376, 38370349, 27147162, 4108046, 17114979, 40823833, 14750693, 261694, 17899416, 36304719, 9646329, 38370349, 8518772, ss227214761, ss237004905, ss243348946, ss482052529, ss483002909, ss485802687, ss491507448, ss537643660, ss564870521, ss660625311, ss779022956, ss783347190, ss784298467, ss832609155, ss833201796, ss834485577, ss992432591, ss1080589035, ss1355977395, ss1427823814, ss1577894834, ss1634304827, ss1677298860, ss1752190372, ss1935857494, ss1968250986, ss2028715725, ss2095066090, ss2157129975, ss2628850413, ss2633311817, ss2701637563, ss2942119714, ss2985066798, ss2985703212, ss3014335205, ss3351408497, ss3627511089, ss3631298626, ss3633119161, ss3633825137, ss3634639923, ss3635513480, ss3636330245, ss3637264907, ss3638122215, ss3640347242, ss3652107666, ss3653838674, ss3681408914, ss3741465828, ss3744940351, ss3753863708, ss3772438653, ss3788022296, ss3793008645, ss3797893537, ss3834546941, ss3840881041, ss3884287739, ss3933646439, ss3984712159, ss6271139551, ss6316065000, ss6322547373, ss6327770855, ss6333122280, ss6346564568, ss6349909945, ss8219197800, ss8315834795, ss8423277073, ss8511599265, ss8624378657, ss8658769607, ss8799404562, ss8846314159, ss8847461571, ss8950183867, ss8979483448, ss8981800139, ss8981800140, ss8982263478 | NC_000016.9:31107688:C:T | NC_000016.10:31096367:C:T | (self) |
| RCV000002295.15, RCV000377657.13, RCV000603173.9, RCV001787364.9, RCV001787365.11, RCV001787366.10, RCV003150805.9, RCV003227593.8, RCV003227594.8, RCV003227595.10, RCV003952337.1, RCV003993732.1, RCV003996074.1, 90705209, 522683700, 1373977, 43560270, 228411008, 9497303021, ss1505810760, ss2211738303, ss3028180750, ss3650498578, ss3699138570, ss3819156746, ss3846372066, ss6162174623, ss6393708372, ss6995223683, ss8012865347, ss8300689691, ss8494114949, ss8603179274, ss8773908237, ss8815894804, ss8851549473, ss8898849591 | NC_000016.10:31096367:C:T | NC_000016.10:31096367:C:T | (self) |
| ss28527760, ss75181539, ss103290726, ss119606770, ss136659349, ss136759876, ss154517329, ss157248916, ss159691137, ss161024963, ss174928603, ss410961014 | NT_010393.16:31047688:C:T | NC_000016.10:31096367:C:T | (self) |
| ss13761958, ss21316156 | NT_024812.10:2507355:C:T | NC_000016.10:31096367:C:T | (self) |
Help
Publications tab displays PubMed articles citing the variation as a listing of PMID, Title, Author, Year, Journal, ordered by Year, descending.
263
citations for rs9923231
| PMID | Title | Author | Year | Journal |
|---|---|---|---|---|
| 15883587 | Common VKORC1 and GGCX polymorphisms associated with warfarin dose. | Wadelius M et al. | 2005 | The pharmacogenomics journal |
| 15888487 | A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. | Yuan HY et al. | 2005 | Human molecular genetics |
| 15930419 | Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. | Rieder MJ et al. | 2005 | The New England journal of medicine |
| 15947090 | The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. | Sconce EA et al. | 2005 | Blood |
| 16270629 | VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. | Geisen C et al. | 2005 | Thrombosis and haemostasis |
| 16580898 | Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. | Aquilante CL et al. | 2006 | Clinical pharmacology and therapeutics |
| 16611310 | The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. | Montes R et al. | 2006 | British journal of haematology |
| 16890578 | VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. | Obayashi K et al. | 2006 | Clinical pharmacology and therapeutics |
| 17048007 | Association of warfarin dose with genes involved in its action and metabolism. | Wadelius M et al. | 2007 | Human genetics |
| 17049586 | Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. | Kimura R et al. | 2007 | Thrombosis research |
| 17387222 | Genetic-based dosing in orthopedic patients beginning warfarin therapy. | Millican EA et al. | 2007 | Blood |
| 17510308 | Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. | Zhu Y et al. | 2007 | Clinical chemistry |
| 17635701 | VKORC1: molecular target of coumarins. | Oldenburg J et al. | 2007 | Journal of thrombosis and haemostasis |
| 18030307 | Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients. | Michaud V et al. | 2008 | Clinical pharmacology and therapeutics |
| 18252229 | Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. | Scott SA et al. | 2008 | American journal of human genetics |
| 18305455 | Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. | Gage BF et al. | 2008 | Clinical pharmacology and therapeutics |
| 18322281 | Genetic determinants of response to warfarin during initial anticoagulation. | Schwarz UI et al. | 2008 | The New England journal of medicine |
| 18466099 | Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. | Limdi NA et al. | 2008 | Pharmacogenomics |
| 18523153 | Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. | Wang D et al. | 2008 | Blood |
| 18535201 | A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. | Cooper GM et al. | 2008 | Blood |
| 18542936 | VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients. | Oner Ozgon G et al. | 2008 | European journal of clinical pharmacology |
| 18559094 | Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction. | Haug KBF et al. | 2008 | Thrombosis journal |
| 18574025 | The largest prospective warfarin-treated cohort supports genetic forecasting. | Wadelius M et al. | 2009 | Blood |
| 18596683 | Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans. | Schelleman H et al. | 2008 | Clinical pharmacology and therapeutics |
| 18629445 | Dependency of phenprocoumon dosage on polymorphisms in the VKORC1 and CYP2C9 genes. | Qazim B et al. | 2009 | Journal of thrombosis and thrombolysis |
| 18662264 | Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. | Lenzini PA et al. | 2008 | Journal of thrombosis and haemostasis |
| 18680736 | Genetic factors contribute to patient-specific warfarin dose for Han Chinese. | Wang TL et al. | 2008 | Clinica chimica acta; international journal of clinical chemistry |
| 18690342 | An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. | Meckley LM et al. | 2008 | Thrombosis and haemostasis |
| 18752379 | Warfarin pharmacogenetics. | Limdi NA et al. | 2008 | Pharmacotherapy |
| 18809808 | Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics. | Johnson JA et al. | 2008 | Circulation |
| 18855533 | VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. | Limdi NA et al. | 2008 | Pharmacogenomics |
| 19018719 | VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients. | Markatos CN et al. | 2008 | Pharmacogenomics |
| 19074728 | Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. | Li C et al. | 2009 | Blood |
| 19135231 | Effect of VKORC1-1639 G>A polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patients. | Yoshizawa M et al. | 2009 | Thrombosis research |
| 19228618 | Estimation of the warfarin dose with clinical and pharmacogenetic data. | Klein TE et al. | 2009 | The New England journal of medicine |
| 19277427 | Pharmacogenetics of acenocoumarol: CYP2C9 *2 and VKORC1 c.-1639G>A, 497C>G, 1173C>T, and 3730G>A variants influence drug dose in anticoagulated patients. | Verde Z et al. | 2009 | Thrombosis and haemostasis |
| 19300499 | A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. | Takeuchi F et al. | 2009 | PLoS genetics |
| 19387626 | Exploring warfarin pharmacogenomics with the extreme-discordant-phenotype methodology: impact of FVII polymorphisms on stable anticoagulation with warfarin. | Fuchshuber-Moraes M et al. | 2009 | European journal of clinical pharmacology |
| 19538716 | Thrombotic genetic risk factors and warfarin pharmacogenetic variants in São Miguel's healthy population (Azores). | Branco CC et al. | 2009 | Thrombosis journal |
| 19582440 | Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients. | Ohno M et al. | 2009 | European journal of clinical pharmacology |
| 19679631 | Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy. | Linder MW et al. | 2009 | Clinical chemistry |
| 19745563 | VKORC1 diplotype-derived dosing model to explain variability in warfarin dose requirements in Asian patients. | Sandanaraj E et al. | 2009 | Drug metabolism and pharmacokinetics |
| 19794411 | Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. | Pautas E et al. | 2010 | Clinical pharmacology and therapeutics |
| 19874474 | Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. | Ferder NS et al. | 2010 | Journal of thrombosis and haemostasis |
| 19875892 | A vitamin K epoxide reductase-oxidase complex gene polymorphism (-1639G>A) and interindividual variability in the dose-effect of vitamin K antagonists. | Stepien E et al. | 2009 | Journal of applied genetics |
| 19940803 | VKORC1 pharmacogenomics summary. | Owen RP et al. | 2010 | Pharmacogenetics and genomics |
| 19955245 | Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. | Moyer TP et al. | 2009 | Mayo Clinic proceedings |
| 20017677 | ARMS test for diagnosis of CYP2C9 and VKORC1 mutation in patients with pulmonary embolism in Han Chinese. | Zhu J et al. | 2010 | Pharmacogenomics |
| 20072124 | Genetic and clinical predictors of warfarin dose requirements in African Americans. | Cavallari LH et al. | 2010 | Clinical pharmacology and therapeutics |
| 20128861 | Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. | Lubitz SA et al. | 2010 | Journal of thrombosis and haemostasis |
| 20149073 | Pharmacogenetics of acenocoumarol in patients with extreme dose requirements. | Pérez-Andreu V et al. | 2010 | Journal of thrombosis and haemostasis |
| 20193673 | Genotype polymorphisms of GGCX, NQO1, and VKORC1 genes associated with risk susceptibility in patients with large-artery atherosclerotic stroke. | Shyu HY et al. | 2010 | Clinica chimica acta; international journal of clinical chemistry |
| 20203262 | Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. | Limdi NA et al. | 2010 | Blood |
| 20339978 | The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population. | Ozer N et al. | 2010 | Heart and vessels |
| 20354686 | Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response. | Molden E et al. | 2010 | European journal of clinical pharmacology |
| 20375999 | Integration of genetic, clinical, and INR data to refine warfarin dosing. | Lenzini P et al. | 2010 | Clinical pharmacology and therapeutics |
| 20376629 | VKORC1 -1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement. | Puehringer H et al. | 2010 | European journal of clinical pharmacology |
| 20386359 | Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study. | McMillin GA et al. | 2010 | Therapeutic drug monitoring |
| 20421126 | A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism. | Wells PS et al. | 2010 | Thrombosis research |
| 20435227 | Clinical assessment incorporating a personal genome. | Ashley EA et al. | 2010 | Lancet (London, England) |
| 20555338 | Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. | Ross KA et al. | 2010 | Journal of human genetics |
| 20585445 | A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants. | Verde Z et al. | 2010 | PloS one |
| 20615525 | VKORC1 V66M mutation in African Brazilian patients resistant to oral anticoagulant therapy. | Orsi FA et al. | 2010 | Thrombosis research |
| 20653676 | CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. | Cen HJ et al. | 2010 | British journal of clinical pharmacology |
| 20709439 | Warfarin dosing in patients with impaired kidney function. | Limdi NA et al. | 2010 | American journal of kidney diseases |
| 20716240 | New genetic variant that might improve warfarin dose prediction in African Americans. | Schelleman H et al. | 2010 | British journal of clinical pharmacology |
| 20733952 | Warfarin genotyping using three different platforms. | Lefferts JA et al. | 2010 | American journal of translational research |
| 20833655 | Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. | Cha PC et al. | 2010 | Human molecular genetics |
| 20833980 | In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. | Nowak-Göttl U et al. | 2010 | Blood |
| 20842355 | VKORC1-1639G>A, CYP2C9, EPHX1691A>G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China. | Gu Q et al. | 2010 | European journal of clinical pharmacology |
| 20854800 | Genotyping three SNPs affecting warfarin drug response by isothermal real-time HDA assays. | Li Y et al. | 2011 | Clinica chimica acta; international journal of clinical chemistry |
| 20921971 | Mapping genes that predict treatment outcome in admixed populations. | Baye TM et al. | 2010 | The pharmacogenomics journal |
| 21044367 | An integrative method for scoring candidate genes from association studies: application to warfarin dosing. | Tatonetti NP et al. | 2010 | BMC bioinformatics |
| 21057703 | Impact of pharmacokinetic (CYP2C9) and pharmacodynamic (VKORC1, F7, GGCX, CALU, EPHX1) gene variants on the initiation and maintenance phases of phenprocoumon therapy. | Luxembourg B et al. | 2011 | Thrombosis and haemostasis |
| 21110013 | Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters. | Geisen C et al. | 2011 | European journal of clinical pharmacology |
| 21110192 | Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations. | Gan GG et al. | 2011 | Annals of hematology |
| 21148049 | Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people. | Esmerian MO et al. | 2011 | Journal of clinical pharmacology |
| 21174619 | VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. | Zambon CF et al. | 2011 | Pharmacogenomics |
| 21176721 | Contribution of 1173C > T polymorphism in the VKORC1 gene to warfarin dose requirements in Han Chinese patients receiving anticoagulation. | Yang J et al. | 2011 | International journal of clinical pharmacology and therapeutics |
| 21179214 | VKORC1 pharmacogenetics and pharmacoproteomics in patients on warfarin anticoagulant therapy: transthyretin precursor as a potential biomarker. | Saminathan R et al. | 2010 | PloS one |
| 21179439 | VKORC1 common variation and bone mineral density in the Third National Health and Nutrition Examination Survey. | Crawford DC et al. | 2010 | PloS one |
| 21185752 | Pharmacogenomics of warfarin dose requirements in Hispanics. | Cavallari LH et al. | 2011 | Blood cells, molecules & diseases |
| 21228733 | Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. | Shahin MH et al. | 2011 | Pharmacogenetics and genomics |
| 21270790 | The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. | Perera MA et al. | 2011 | Clinical pharmacology and therapeutics |
| 21318593 | The influence of genetic polymorphisms and interacting drugs on initial response to warfarin in Chinese patients with heart valve replacement. | Zhong SL et al. | 2011 | European journal of clinical pharmacology |
| 21320153 | Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry. | Botton MR et al. | 2011 | British journal of clinical pharmacology |
| 21562147 | Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose. | Zhang X et al. | 2011 | Drug metabolism and disposition |
| 21575037 | Population diversity and the performance of warfarin dosing algorithms. | Suarez-Kurtz G et al. | 2011 | British journal of clinical pharmacology |
| 21637794 | Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue. | Innocenti F et al. | 2011 | PLoS genetics |
| 21639946 | Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians. | Suriapranata IM et al. | 2011 | BMC medical genetics |
| 21672908 | Facilitating pharmacogenetic studies using electronic health records and natural-language processing: a case study of warfarin. | Xu H et al. | 2011 | Journal of the American Medical Informatics Association |
| 21691466 | Genetics of warfarin sensitivity in an emergency department population with thromboembolic. | Johnson SW et al. | 2011 | The western journal of emergency medicine |
| 21747589 | The impact of VKORC1-1639 G>A polymorphism on the maintenance dose of oral anticoagulants for thromboembolic prophylaxis in North India: A pilot study. | Rathore SS et al. | 2011 | Indian journal of human genetics |
| 21900891 | Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. | Johnson JA et al. | 2011 | Clinical pharmacology and therapeutics |
| 21918509 | Pharmacogenomics: application to the management of cardiovascular disease. | Johnson JA et al. | 2011 | Clinical pharmacology and therapeutics |
| 21935354 | Phased whole-genome genetic risk in a family quartet using a major allele reference sequence. | Dewey FE et al. | 2011 | PLoS genetics |
| 22010099 | VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. | Biss TT et al. | 2012 | Blood |
| 22023024 | The pharmacogenetics of the response to warfarin in Chinese. | Lam MP et al. | 2012 | British journal of clinical pharmacology |
| 22040439 | Extremely low warfarin dose in patients with genotypes of CYP2C9*3/*3 and VKORC1-1639A/A. | Gao L et al. | 2011 | Chinese medical journal |
| 22114699 | Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation. | Gong IY et al. | 2011 | PloS one |
| 22116191 | The Creating an Optimal Warfarin Nomogram (CROWN) Study. | Perlstein TS et al. | 2012 | Thrombosis and haemostasis |
| 22122181 | Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. | Cavallari LH et al. | 2011 | Pharmacotherapy |
| 22130800 | Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. | Moreau C et al. | 2012 | Blood |
| 22135769 | Gene-drug interaction in stroke. | Amici S et al. | 2011 | Stroke research and treatment |
| 22158446 | Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans. | Cavallari LH et al. | 2012 | Pharmacogenetics and genomics |
| 22178823 | [Distribution of variant alleles association with warfarin pharmacokinetics and pharmacodynamics in the Han population in China]. | Liu Y et al. | 2011 | Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences |
| 22186998 | Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. | Horne BD et al. | 2012 | Thrombosis and haemostasis |
| 22274142 | Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes. | Valentin II et al. | 2012 | The Annals of pharmacotherapy |
| 22329724 | Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. | Ramirez AH et al. | 2012 | Pharmacogenomics |
| 22349464 | A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms. | Cini M et al. | 2012 | European journal of clinical pharmacology |
| 22486182 | Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients. | Smires FZ et al. | 2012 | Journal of clinical pharmacy and therapeutics |
| 22528326 | Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients. | Liang R et al. | 2012 | Journal of thrombosis and thrombolysis |
| 22563365 | Pharmacogenomic Research in South Africa: Lessons Learned and Future Opportunities in the Rainbow Nation. | Warnich L et al. | 2011 | Current pharmacogenomics and personalized medicine |
| 22571356 | Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates. | Lund K et al. | 2012 | British journal of haematology |
| 22592842 | Oral anticoagulation and VKORC1 polymorphism in patients with a mechanical heart prosthesis: a 6-year follow-up. | Giansante C et al. | 2012 | Journal of thrombosis and thrombolysis |
| 22629463 | Therapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north Indians. | Rathore SS et al. | 2012 | PloS one |
| 22630332 | Pharmacogene regulatory elements: from discovery to applications. | Smith RP et al. | 2012 | Genome medicine |
| 22676192 | Retrospective evidence for clinical validity of expanded genetic model in warfarin dose optimization in a South Indian population. | Pavani A et al. | 2012 | Pharmacogenomics |
| 22676711 | Pharmacogenomics of warfarin in populations of African descent. | Suarez-Kurtz G et al. | 2013 | British journal of clinical pharmacology |
| 22754184 | Pharmacogenetic aspects of coumarinic oral anticoagulant therapies. | Rathore SS et al. | 2011 | Indian journal of clinical biochemistry |
| 22854539 | Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients. | Pathare A et al. | 2012 | Journal of human genetics |
| 22911785 | An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease. | Borobia AM et al. | 2012 | PloS one |
| 22938532 | Sequencing and analysis of a South Asian-Indian personal genome. | Gupta R et al. | 2012 | BMC genomics |
| 22952875 | Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. | Jorgensen AL et al. | 2012 | PloS one |
| 22990331 | CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation. | Santos PC et al. | 2013 | European journal of clinical pharmacology |
| 22992668 | Pharmacogenomics knowledge for personalized medicine. | Whirl-Carrillo M et al. | 2012 | Clinical pharmacology and therapeutics |
| 23016735 | Personalized approach of medication by indirect anticoagulants tailored to the patient-Russian context: what are the prospects? | Belozerceva LA et al. | 2012 | The EPMA journal |
| 23061746 | Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population. | Özer M et al. | 2013 | Basic & clinical pharmacology & toxicology |
| 23104259 | Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin. | Ma C et al. | 2012 | International journal of hematology |
| 23124848 | Brief Report: Single-nucleotide polymorphisms in VKORC1 are risk factors for systemic lupus erythematosus in Asians. | Kaiser R et al. | 2013 | Arthritis and rheumatism |
| 23133420 | Pharmacogenomic Diversity among Brazilians: Influence of Ancestry, Self-Reported Color, and Geographical Origin. | Suarez-Kurtz G et al. | 2012 | Frontiers in pharmacology |
| 23159639 | The impact of the CYP2C9 and VKORC1 polymorphisms on acenocoumarol dose requirements in a Romanian population. | Buzoianu AD et al. | 2013 | Blood cells, molecules & diseases |
| 23226061 | The role of genetics in pre-eclampsia and potential pharmacogenomic interventions. | Williams PJ et al. | 2012 | Pharmacogenomics and personalized medicine |
| 23237631 | Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial. | Carcas AJ et al. | 2012 | Trials |
| 23279643 | The VKORC1 and CYP2C9 genotypes are associated with over-anticoagulation during initiation of warfarin therapy in children. | Biss TT et al. | 2013 | Journal of thrombosis and haemostasis |
| 23285254 | Positive selection in the chromosome 16 VKORC1 genomic region has contributed to the variability of anticoagulant response in humans. | Patillon B et al. | 2012 | PloS one |
| 23299853 | Randomised trial of a clinical dosing algorithm to start anticoagulation with phenprocoumon. | Caduff Good A et al. | 2013 | Swiss medical weekly |
| 23300409 | Chapter 7: Pharmacogenomics. | Karczewski KJ et al. | 2012 | PLoS computational biology |
| 23423913 | Mechanical heart valve recipients: anticoagulation in patients with genetic variations of phenprocoumon metabolism. | Brehm K et al. | 2013 | European journal of cardio-thoracic surgery |
| 23473641 | Effect of CYP2C9 and VKORC1 genetic polymorphisms on mean daily maintenance dose of acenocoumarol in South Indian patients. | Krishna Kumar D et al. | 2013 | Thrombosis research |
| 23481074 | Cytochrome P450 (CYP2C9*2,*3) & vitamin-K epoxide reductase complex (VKORC1 -1639G<A) gene polymorphisms & their effect on acenocoumarol dose in patients with mechanical heart valve replacement. | Kaur A et al. | 2013 | The Indian journal of medical research |
| 23602689 | Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage, over anticoagulation and other adverse outcomes in Indian population. | Gaikwad T et al. | 2013 | European journal of pharmacology |
| 23651023 | Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment. | Gschwind L et al. | 2013 | Pharmacogenomics |
| 23691226 | Novel associations of VKORC1 variants with higher acenocoumarol requirements. | Anton AI et al. | 2013 | PloS one |
| 23732872 | Association of VKORC1-1639G>A polymorphism with susceptibility to ossification of the posterior longitudinal ligament of the spine: a Korean study. | Chin DK et al. | 2013 | Acta neurochirurgica |
| 23774941 | An acenocoumarol dose algorithm based on a South-Eastern European population. | Pop TR et al. | 2013 | European journal of clinical pharmacology |
| 23797323 | Pharmacogenomics of anti-platelet and anti-coagulation therapy. | Fisch AS et al. | 2013 | Current cardiology reports |
| 23835662 | Pharmacogenomics, ancestry and clinical decision making for global populations. | Ramos E et al. | 2014 | The pharmacogenomics journal |
| 23949431 | Cytochrome P450 oxidoreductase genetic polymorphisms A503V and rs2868177 do not significantly affect warfarin stable dosage in Han-Chinese patients with mechanical heart valve replacement. | Tan SL et al. | 2013 | European journal of clinical pharmacology |
| 23972066 | Role of the vitamin K epoxide reductase complex subunit 1 (VKORC1) -1639G>A gene polymorphism in patients with retinal vein occlusion. | Weger M et al. | 2013 | Current eye research |
| 23990957 | Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model. | Mazzaccara C et al. | 2013 | PloS one |
| 24018621 | Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans. | Hernandez W et al. | 2014 | The pharmacogenomics journal |
| 24019055 | Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population. | Krishna Kumar D et al. | 2014 | European journal of clinical pharmacology |
| 24029542 | Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects. | Kadian-Dodov DL et al. | 2013 | Vascular medicine (London, England) |
| 24108193 | Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm. | Wolkanin-Bartnik J et al. | 2013 | Pharmacogenetics and genomics |
| 24224579 | A new algorithm for weekly phenprocoumon dose variation in a southern Brazilian population: role for CYP2C9, CYP3A4/5 and VKORC1 genes polymorphisms. | Botton MR et al. | 2014 | Basic & clinical pharmacology & toxicology |
| 24330000 | Characterizing variability in warfarin dose requirements in children using modelling and simulation. | Hamberg AK et al. | 2014 | British journal of clinical pharmacology |
| 24474498 | VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. | Shaw K et al. | 2014 | Pediatric blood & cancer |
| 24601977 | The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population. | Vear SI et al. | 2014 | British journal of haematology |
| 24787444 | An ontology-based, mobile-optimized system for pharmacogenomic decision support at the point-of-care. | Miñarro-Giménez JA et al. | 2014 | PloS one |
| 24956252 | Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment. | Cerezo-Manchado JJ et al. | 2014 | Pharmacogenomics |
| 24966969 | High resolution melting method to detect single nucleotide polymorphism of VKORC1 and CYP2C9. | Chen C et al. | 2014 | International journal of clinical and experimental pathology |
| 25001883 | Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects. | Hawcutt DB et al. | 2014 | The pharmacogenomics journal |
| 25042728 | Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms. | Wypasek E et al. | 2014 | Thrombosis research |
| 25069408 | Multiplex pyrosequencing method to determine CYP2C9*3, VKORC1*2, and CYP4F2*3 polymorphisms simultaneously: its application to a Korean population and comparisons with other ethnic groups. | Kim KA et al. | 2014 | Molecular biology reports |
| 25069476 | Clinical and pharmacogenomic implications of genetic variation in a Southern Ethiopian population. | Tekola-Ayele F et al. | 2015 | The pharmacogenomics journal |
| 25084205 | Methodological issues in the development of a pharmacogenomic algorithm for warfarin dosing: comparison of two regression approaches. | Pavani A et al. | 2014 | Pharmacogenomics |
| 25148255 | Determinants of the over-anticoagulation response during warfarin initiation therapy in Asian patients based on population pharmacokinetic-pharmacodynamic analyses. | Ohara M et al. | 2014 | PloS one |
| 25244877 | Pharmacogenetic association study of warfarin safety endpoints in Puerto Ricans. | Valentín II et al. | 2014 | Puerto Rico health sciences journal |
| 25312789 | Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 genes and the therapeutic warfarin dose in Brazilian patients with thrombosis: a prospective cohort study. | de Oliveira Almeida VC et al. | 2014 | Molecular diagnosis & therapy |
| 25419701 | Exploring the distribution of genetic markers of pharmacogenomics relevance in Brazilian and Mexican populations. | Bonifaz-Peña V et al. | 2014 | PloS one |
| 25519826 | An acenocoumarol dosing algorithm exploiting clinical and genetic factors in South Indian (Dravidian) population. | Krishna Kumar D et al. | 2015 | European journal of clinical pharmacology |
| 25594941 | Warfarin dosage response related pharmacogenetics in Chinese population. | Li S et al. | 2015 | PloS one |
| 25714468 | A systematic approach to the reporting of medically relevant findings from whole genome sequencing. | McLaughlin HM et al. | 2014 | BMC medical genetics |
| 25769357 | Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. | Mega JL et al. | 2015 | Lancet (London, England) |
| 25897256 | Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics. | Beitelshees AL et al. | 2015 | Pharmacogenomics and personalized medicine |
| 26024874 | Race influences warfarin dose changes associated with genetic factors. | Limdi NA et al. | 2015 | Blood |
| 26219158 | The Influence of VKORC1 Polymorphisms on Warfarin Doses in Thai Patients with Deep Vein Thrombosis. | Sermsathanasawadi N et al. | 2015 | Journal of the Medical Association of Thailand = Chotmaihet thangphaet |
| 26238769 | Impact of regular physical activity on weekly warfarin dose requirement. | Rouleau-Mailloux É et al. | 2016 | Journal of thrombosis and thrombolysis |
| 26249541 | Effects of single nucleotide polymorphisms in c-Myc on stable warfarin doses in patients with cardiac valve replacements. | Lee KE et al. | 2015 | Pharmacogenomics |
| 26433837 | The influence of VKORC1 gene polymorphism on warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis. | Zhang J et al. | 2015 | Thrombosis research |
| 26444257 | Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics. | Chan SL et al. | 2016 | Pharmacogenetics and genomics |
| 26445138 | VKORC1 gene polymorphisms and adverse events in Croatian patients on warfarin therapy. | Mandic D et al. | 2015 | International journal of clinical pharmacology and therapeutics |
| 26600534 | VKORC1 rs2359612 and rs9923231 polymorphisms correlate with high risks of cardiovascular and cerebrovascular diseases. | Li Y et al. | 2015 | Genetics and molecular research |
| 26739746 | A multi-factorial analysis of response to warfarin in a UK prospective cohort. | Bourgeois S et al. | 2016 | Genome medicine |
| 26745506 | A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics. | Duconge J et al. | 2016 | PloS one |
| 26847243 | Novel regulatory variant detected on the VKORC1 haplotype that is associated with warfarin dose. | Cavalli M et al. | 2016 | Pharmacogenomics |
| 26858644 | Cross-Comparison of Exome Analysis, Next-Generation Sequencing of Amplicons, and the iPLEX(®) ADME PGx Panel for Pharmacogenomic Profiling. | Chua EW et al. | 2016 | Frontiers in pharmacology |
| 26940072 | Association of Genetic Polymorphisms in the VKORC1 and CYP2C9 Genes with Warfarin Dosage in a Group of Kuwaiti Individuals. | Alrashid MH et al. | 2016 | Molecular diagnosis & therapy |
| 26941429 | Advancing Pharmacogenomics Education in the Core PharmD Curriculum through Student Personal Genomic Testing. | Adams SM et al. | 2016 | American journal of pharmaceutical education |
| 26977927 | A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish Population. | Tong HY et al. | 2016 | PloS one |
| 27090252 | A whole genome analyses of genetic variants in two Kelantan Malay individuals. | Wan Juhari WK et al. | 2014 | The HUGO journal |
| 27262824 | Effect of VKORC1, CYP2C9, CFP4F2, and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients. | Wakamiya T et al. | 2016 | Molecular diagnosis & therapy |
| 27453700 | Prediction of Warfarin Dose in Pediatric Patients: An Evaluation of the Predictive Performance of Several Models. | Marek E et al. | 2016 | The journal of pediatric pharmacology and therapeutics |
| 27617219 | Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis. | Zhang J et al. | 2016 | Meta gene |
| 27703968 | G-1639A but Not C1173T VKORC1 Gene Polymorphism Is Related to Ischemic Stroke and Its Various Risk Factors in Ukrainian Population. | Dubovyk YI et al. | 2016 | BioMed research international |
| 28029011 | Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines. | Kim S et al. | 2017 | Annals of laboratory medicine |
| 28049362 | Warfarin Dose Model for the Prediction of Stable Maintenance Dose in Indian Patients. | Gaikwad T et al. | 2018 | Clinical and applied thrombosis/hemostasis |
| 28079798 | Clinical and genetic factors associated with warfarin maintenance dose in northern Chinese patients with mechanical heart valve replacement. | Liu R et al. | 2017 | Medicine |
| 28135054 | Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans. | Hernandez W et al. | 2017 | Journal of thrombosis and haemostasis |
| 28222321 | The VKORC1 polymorphism rs9923231 is associated with aneurysms of the ascending aorta in an Austrian population. | Andreas M et al. | 2017 | Thrombosis research |
| 28281786 | Susceptiveness of Vitamin K epOxide Reductase Complex Subunit 1 Gene Polymorphism in Essential Hypertension. | Turgut Cosan D et al. | 2017 | Genetic testing and molecular biomarkers |
| 28384046 | Cross-Validation of High-Resolution Melting Analysis-Based Genotyping Platform. | Langaee T et al. | 2017 | Genetic testing and molecular biomarkers |
| 28401802 | The Impact of Gene Polymorphisms on Anticoagulation Control With Warfarin. | Jiang HH et al. | 2018 | Clinical and applied thrombosis/hemostasis |
| 28620303 | Effect of Genetic Variability in the CYP4F2, CYP4F11, and CYP4F12 Genes on Liver mRNA Levels and Warfarin Response. | Zhang JE et al. | 2017 | Frontiers in pharmacology |
| 28817838 | Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228). | Lévi F et al. | 2017 | British journal of cancer |
| 28867752 | Genotyping of CYP2C9 and VKORC1 polymorphisms predicts south Indian patients with deep vein thrombosis as fast metabolizers of warfarin/acenocoumarin. | Arunkumar G et al. | 2017 | Drug discoveries & therapeutics |
| 29190926 | Polymorphism of the ABO gene associate with thrombosis risk in patients with paroxysmal nocturnal hemoglobinuria. | Long Z et al. | 2017 | Oncotarget |
| 29201112 | Association of Warfarin Therapy with APOE and VKORC1 Genes Polymorphism in Iranian Population. | Rafiee S et al. | 2017 | Iranian journal of pharmaceutical research |
| 29218998 | VKORC1-1639A allele influences warfarin maintenance dosage among Blacks receiving warfarin anticoagulation: a retrospective cohort study. | Mili FD et al. | 2018 | Future cardiology |
| 29234073 | Identification of two novel genes SLC15A2 and SLCO1B3 associated with maintenance dose variability of warfarin in a Chinese population. | Cai LL et al. | 2017 | Scientific reports |
| 29469681 | Lack of Association Between Type 2 Diabetes and the 3673G / A and 9041G / A Gene Variants of Vitamin K Epoxide Reductase Complex Subunit 1 (VKORC1). | Ozbayer C et al. | 2016 | International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition |
| 29713005 | Genetic structure of pharmacogenetic biomarkers in Brazil inferred from a systematic review and population-based cohorts: a RIBEF/EPIGEN-Brazil initiative. | Rodrigues-Soares F et al. | 2018 | The pharmacogenomics journal |
| 29776219 | A simulation of warfarin maintenance dose requirement using a pharmacogenetic algorithm in an ethnically diverse cohort. | Gladding P et al. | 2010 | Personalized medicine |
| 29776386 | Impact of VKORC1, CYP4F2 and NQO1 gene variants on warfarin dose requirement in Han Chinese patients with catheter ablation for atrial fibrillation. | Li J et al. | 2018 | BMC cardiovascular disorders |
| 30099920 | Genetic Polymorphism of VKORC1-1639 in Children With Intracranial Hemorrhage Due to Vitamin K Deficiency. | Berber U et al. | 2018 | Clinical and applied thrombosis/hemostasis |
| 30452466 | Characterization of ADME genes variation in Roma and 20 populations worldwide. | Škarić-Jurić T et al. | 2018 | PloS one |
| 30486437 | Impact of CYP2C9 and VKORC1 Polymorphisms on Warfarin Sensitivity and Responsiveness in Jordanian Cardiovascular Patients during the Initiation Therapy. | Al-Eitan LN et al. | 2018 | Genes |
| 30595241 | Value of VKORC1 (-1639G>A) rs9923231 genotyping in predicting warfarin dose: A replication study in South Indian population. | Harikrishnan S et al. | 2018 | Indian heart journal |
| 30712247 | Interpretation of the effect of CYP2C9, VKORC1 and CYP4F2 variants on warfarin dosing adjustment in Turkey. | Kocael A et al. | 2019 | Molecular biology reports |
| 30758238 | Development and Cross-Validation of High-Resolution Melting Analysis-Based Cardiovascular Pharmacogenetics Genotyping Panel. | Langaee T et al. | 2019 | Genetic testing and molecular biomarkers |
| 30866412 | VKORC1 and CYP2C9 Polymorphisms: A Case Report in a Dutch Family with Pulmonary Fibrosis. | Wijnen P et al. | 2019 | International journal of molecular sciences |
| 30933373 | Warfarin dose requirement in patients having severe thrombosis or thrombophilia. | Helin TA et al. | 2019 | British journal of clinical pharmacology |
| 31019283 | Secondary actionable findings identified by exome sequencing: expected impact on the organisation of care from the study of 700 consecutive tests. | Thauvin-Robinet C et al. | 2019 | European journal of human genetics |
| 31105858 | Impact of gene polymorphism on the initiation and maintenance phases of warfarin therapy in Chinese patients undergoing heart valve replacement. | Liu J et al. | 2019 | American journal of translational research |
| 31114289 | VKORC1 variants as significant predictors of warfarin dose in Emiratis. | Al-Mahayri ZN et al. | 2019 | Pharmacogenomics and personalized medicine |
| 31228854 | Label-free discrimination of single nucleotide changes in DNA by reflectometric interference Fourier transform spectroscopy. | Makiyan F et al. | 2019 | Colloids and surfaces. B, Biointerfaces |
| 31395958 | Algorithm for predicting low maintenance doses of warfarin using age and polymorphisms in genes CYP2C9 and VKORC1 in Brazilian subjects. | de Oliveira Magalhães Mourão A et al. | 2020 | The pharmacogenomics journal |
| 31720756 | Non-genetic factors and polymorphisms in genes CYP2C9 and VKORC1: predictive algorithms for TTR in Brazilian patients on warfarin. | Praxedes MFS et al. | 2020 | European journal of clinical pharmacology |
| 31854268 | Impact of CYP2C9, VKORC1, ApoE and ABCB1 polymorphisms on stable warfarin dose requirements in elderly Chinese patients. | Li W et al. | 2020 | Pharmacogenomics |
| 31869433 | Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-Analysis. | Asiimwe IG et al. | 2020 | Clinical pharmacology and therapeutics |
| 31973625 | Prioritizing rs7294 as a mirSNP contributing to warfarin dosing variability. | Koshy L et al. | 2020 | Pharmacogenomics |
| 32228310 | Functionally Significant Coumarin-Related Variant Alleles and Time to Therapeutic Range in Chilean Cardiovascular Patients. | Rojo M et al. | 2020 | Clinical and applied thrombosis/hemostasis |
| 32326111 | Role of Genetic Variations in the Hepatic Handling of Drugs. | Marin JJG et al. | 2020 | International journal of molecular sciences |
| 32327994 | A Pharmacogenetically Guided Acenocoumarol Dosing Algorithm for Chilean Patients: A Discovery Cohort Study. | Roco A et al. | 2020 | Frontiers in pharmacology |
| 32380173 | Recommendations for Clinical Warfarin Genotyping Allele Selection: A Report of the Association for Molecular Pathology and the College of American Pathologists. | Pratt VM et al. | 2020 | The Journal of molecular diagnostics |
| 32559398 | Effects of EPHX1 rs2260863 polymorphisms on warfarin maintenance dose in very elderly, frail Han-Chinese population. | Lin X et al. | 2020 | Pharmacogenomics |
| 32669629 | The effect of the VKORC1 promoter variant on warfarin responsiveness in the Saudi WArfarin Pharmacogenetic (SWAP) cohort. | Al Ammari M et al. | 2020 | Scientific reports |
| 33061049 | Genetic polymorphisms and dosing of vitamin K antagonist in Indian patients after heart valve surgery. | Choudhary SK et al. | 2019 | Indian journal of thoracic and cardiovascular surgery |
| 33234259 | Genetic Variation in VKORC1 and Risk for Osteoporosis. | He J et al. | 2021 | Archives of medical research |
| 33262486 | Abstracts from the 53rd European Society of Human Genetics (ESHG) Conference: e-Posters. | 2020 | European journal of human genetics | |
| 33278335 | Implications of Polymorphisms in the BCKDK and GATA-4 Gene Regions on Stable Warfarin Dose in African Americans. | Bargal SA et al. | 2021 | Clinical and translational science |
| 33430289 | Combination of Genome-Wide Polymorphisms and Copy Number Variations of Pharmacogenes in Koreans. | Han N et al. | 2021 | Journal of personalized medicine |
| 33519226 | Genetic Diversity of Drug-Related Genes in Native Americans of the Brazilian Amazon. | Fernandes MR et al. | 2021 | Pharmacogenomics and personalized medicine |
| 33682710 | Variation in VKORC1 Is Associated with Vascular Dementia. | Mur J et al. | 2021 | Journal of Alzheimer's disease |
| 33763108 | Whole Genome Interpretation for a Family of Five. | Corpas M et al. | 2021 | Frontiers in genetics |
| 33811620 | Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study. | Sridharan K et al. | 2021 | Pharmacological reports |
| 34250965 | Performance Evaluation of Warfarin Dose Prediction Algorithms and Effects of Clinical Factors on Warfarin Dose in Chinese Patients. | Gao W et al. | 2021 | Therapeutic drug monitoring |
| 34357562 | Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients. | Hirata TDC et al. | 2021 | Molecular diagnosis & therapy |
| 34382722 | Profiling of warfarin pharmacokinetics-associated genetic variants: Black Africans portray unique genetic markers important for an African specific warfarin pharmacogenetics-dosing algorithm. | Ndadza A et al. | 2021 | Journal of thrombosis and haemostasis |
| 34559488 | Retrospective pharmacogenetic analysis of a pediatric patient under anticoagulant treatment: Clinical case. | Cavieres M et al. | 2021 | Biomedica |
| 34606635 | Effect of NPC1L1 polymorphism on warfarin stable dose in Chinese patients under heart valve replacement surgery. | Ma S et al. | 2022 | Clinical and experimental pharmacology & physiology |
| 34621706 | Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform. | Kim B et al. | 2021 | Translational and clinical pharmacology |
| 34958284 | Warfarin Pharmacogenomics for Precision Medicine in Real-Life Clinical Practice in Southern Africa: Harnessing 73 Variants in 29 Pharmacogenes. | Muyambo S et al. | 2022 | Omics |
| 35091749 | Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa. | Haas DW et al. | 2022 | The Journal of infectious diseases |
| 35608144 | Pharmacogenetic variants influence vitamin K anticoagulant dosing in patients with mechanical prosthetic heart valves. | Koshy L et al. | 2022 | Pharmacogenomics |
| 35629166 | Association of Genetic Polymorphisms with Complications of Implanted LVAD Devices in Patients with Congestive Heart Failure: A Kazakhstani Study. | Zhalbinova MR et al. | 2022 | Journal of personalized medicine |
| 35743738 | Pharmacogenomic Profile of Amazonian Amerindians. | Rodrigues JCG et al. | 2022 | Journal of personalized medicine |
| 35757332 | Determination of Pleiotropic Effect of Warfarin in VKORC1 and CYP2C9 Genotypes in Patients With Heart Valve Replacement. | Shafique H et al. | 2022 | Frontiers in cardiovascular medicine |
| 35866816 | Impact of VKORC1, CYP2C9, CYP1A2, UGT1A1, and GGCX polymorphisms on warfarin maintenance dose: Exploring a new algorithm in South Chinese patients accept mechanical heart valve replacement. | Li J et al. | 2022 | Medicine |
| 36164570 | Prevalence of exposure to pharmacogenetic drugs by the Saudis treated at the health care centers of the Ministry of National Guard. | Alshabeeb MA et al. | 2022 | Saudi pharmaceutical journal |
| 36210801 | A genome-wide association study of plasma concentrations of warfarin enantiomers and metabolites in sub-Saharan black-African patients. | Asiimwe IG et al. | 2022 | Frontiers in pharmacology |
| 36335097 | Analysis of clinically relevant variants from ancestrally diverse Asian genomes. | Chan SH et al. | 2022 | Nature communications |
Help
The Flanks tab provides retrieving flanking sequences of a SNP on all molecules that have placements.
Genome context:
Select flank length:
Genomic regions, transcripts, and products
Top▲
Help
NCBI Graphical Sequence Viewer display of the genomic region, transcripts and protein products for the reported RefSNP (rs).
Use the zoom option to view the nucleotides around the RefSNP and find other neighboring RefSNPs.
Visit Sequence Viewer for help with navigating inside the display and modifying the selection of displayed data tracks.
NCBI Graphical Sequence Viewer display of the genomic region, transcripts and protein products for the reported RefSNP (rs).
Use the zoom option to view the nucleotides around the RefSNP and find other neighboring RefSNPs.
Visit Sequence Viewer for help with navigating inside the display and modifying the selection of displayed data tracks.